T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2251
Vestis
VSTS
$1.87B
| $677K | ﹤0.01% |
101,368
-4,127
| -4% | -$24.1K |
|
2252
Yext
YEXT
$574M
| $673K | ﹤0.01% |
83,431
+6,877
| +9% | +$57.9K |
|
2253
Limbach Holdings
LMB
$536M
| $672K | ﹤0.01% |
8,623
-643
| -7% | -$52.9K |
|
2254
Invesco Mortgage Capital
IVR
$802M
| $670K | ﹤0.01% |
79,614
-8,348
| -9% | -$65.4K |
|
2255
Taysha Gene Therapies
TSHA
$1.92B
| $670K | ﹤0.01% |
121,814
+7,979
| +7% | +$38.7K |
|
2256
Capricor Therapeutics
CAPR
$244M
| $669K | ﹤0.01% |
23,152
+2,578
| +13% | +$33.7K |
|
2257
Old Second Bancorp
OSBC
$1.31B
| $669K | ﹤0.01% |
34,262
+2,019
| +6% | +$37.7K |
|
2258
Phibro Animal Health
PAHC
$1.37B
| $669K | ﹤0.01% |
17,887
+766
| +4% | +$31.1K |
|
2259
Sharplink Inc
SBET
$1.37B
| $669K | ﹤0.01% |
74,785
+53,100
| +245% | +$649K |
|
2260
Sprout Social
SPT
$579M
| $667K | ﹤0.01% |
59,150
-948
| -2% | -$10.2K |
|
|
NNE
2261
Nano Nuclear Energy
NNE
$1.1B
| $667K | ﹤0.01% |
27,743
+11,073
| +66% | +$424K |
|
2262
CVR Energy
CVI
$3.52B
| $665K | ﹤0.01% |
26,138
-5,355
| -17% | -$182K |
|
2263
Eagle Bancorp
EGBN
$877M
| $665K | ﹤0.01% |
31,023
| – | – |
|
2264
NextDecade
NEXT
$1.8B
| $659K | ﹤0.01% |
124,905
+22,475
| +22% | +$134K |
|
|
PLGO
2265
Pelagos Insurance Capital
PLGO
$2.08B
| $656K | ﹤0.01% |
33,490
+2,395
| +8% | +$44.7K |
|
|
FIGR
2266
Figure Technology Solutions
FIGR
$6.78B
| $651K | ﹤0.01% |
+15,939
| New | +$638K |
|
2267
Defiance Quantum ETF
QTUM
$5.82B
| $646K | ﹤0.01% |
5,890
| – | – |
|
2268
SITE Centers
SITC
$156M
| $645K | ﹤0.01% |
100,420
+15,200
| +18% | +$115K |
|
2269
Bank First Corp
BFC
$1.74B
| $643K | ﹤0.01% |
5,276
+256
| +5% | +$32.6K |
|
|
ONT
2270
Onterris Inc
ONT
$576M
| $641K | ﹤0.01% |
25,787
+1,167
| +5% | +$30.8K |
|
|
REFI
2271
Chicago Atlantic Real Estate Finance
REFI
$268M
| $640K | ﹤0.01% |
52,196
+11,875
| +29% | +$152K |
|
2272
SolarEdge
SEDG
$1.98B
| $640K | ﹤0.01% |
22,173
+11,933
| +117% | +$416K |
|
|
PSTL
2273
Postal Realty Trust
PSTL
$701M
| $638K | ﹤0.01% |
39,500
+15,072
| +62% | +$232K |
|
2274
Amprius Technologies
AMPX
$1.74B
| $636K | ﹤0.01% |
80,578
+31,463
| +64% | +$360K |
|
2275
SunCoke Energy
SXC
$801M
| $631K | ﹤0.01% |
87,603
+3,936
| +5% | +$29K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.